Trial · NCT03126812
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
NCT03126812, Phase 1, Phase 2, Completed, The Netherlands Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer. Trials, record NCT03126812. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03126812
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
- NCT number
- NCT03126812
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 33 participants, actual
- Lead sponsor
- The Netherlands Cancer Institute
- Conditions
- Ovarian Cancer Stage IV, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Carboplatin, Paclitaxel, Pembrolizumab
- First posted
- 2017-04-24
- Last updated
- 2024-05-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of T-cells in peripheral blood | up to week 52 | determine the number of T cells in peripheral blood samples and tissue samples |
| Secondary | Toxicity; Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0 | up to 30 days after end of treatment | Toxicity will be analyzed in patients who have received at least one administration of pembrolizumab. |
| Secondary | Response Rate | at week 12, debulking surgery | number of patients with no viable invasive tumor left in the resection specimen |
| Secondary | Response rate according to RECIST | at week 3 and 6 | Number of patients with partial or complete response according to RECIST |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03126812
GET https://conductscience.org/api/trials/v1/NCT03126812/registered